Vidalta 10

Country: New Zealand

Bahasa: Inggeris

Sumber: Ministry for Primary Industries

Bahan aktif:

carbimazole

Boleh didapati daripada:

Schering-Plough Animal Health Limited

INN (Nama Antarabangsa):

carbimazole

Komposisi:

carbimazole 100 g/kg

Kawasan terapeutik:

Endocrine agent (hormone)

Status kebenaran:

ACVM Registered

Tarikh kebenaran:

2011-06-14

Ciri produk

VIDALTA 10
30 and 100 tablets – Leaflet, Carton and Label
Page 1 of 7
Vidalta 10
26-Mar-20
Leaflet
DANGER
RESTRICTED VETERINARY MEDICINE
KEEP OUT OF THE REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY
VIDALTA
® 10
100 MG TABLETS FOR CATS (CONTAINING 10 MG OF CARBIMAZOLE)
VIDALTA 10 are round pink tablets, each containing 10 mg carbimazole
and 0.25 mg red ferric
oxide (E 172).
READ ENTIRE LEAFLET BEFORE USE.
INDICATIONS
For the treatment of hyperthyroidism and hyperthyroidism-associated
clinical signs in cats.
DIRECTIONS FOR USE
DOSAGE AND ADMINISTRATION
For oral use only.
VIDALTA 10 tablets should be administered at the same time every day,
in particular with
relation to feeding.
Do not break or crush VIDALTA 10 tablets as this will affect the
sustained release properties of
the tablet.
The prolonged release formulation of VIDALTA 10 enables a 24-hour
dosing interval.
The aim of treatment is to maintain total thyroxin concentrations
(TT4) in the lower end of the
reference range. Accordingly, the following dose recommendations for
dosing during
adjustment and maintenance phases are suggested. However, dosing
adjustment should be
primarily based upon the clinical assessment of the individual cat.
Monitoring of TT4, full
haematology and liver and kidney parameters is advised at each
recommended follow up
visit.
Adjustment phase
The starting dose is a single daily oral administration of one tablet
of Vidalta 15 (A011752,
15 mg carbimazole) per cat. Consideration could be given to a starting
dose of VIDALTA 10
(10 mg carbimazole) daily where the TT4 concentration is only mildly
increased, e.g.
between 50 nmol/L and 100 nmol/L. With the recommended starting dose
of one Vidalta 15
tablet once daily, total thyroxin concentration (TT4) may decrease to
within the euthyroid
range (TT4<50 nmol/L) shortly after treatment initiation. A dose
adjustment may be required
as early as 10 days after commencing treatment. Dose adjustment should
be also performed
3, 5 and 8 weeks after initiation of treatment, depending on both
clinical